Original Article Effects of second-generation antipsychotic medications treatment: cognitive improvement in Chinese patients with schizophrenia

Hailing Li, Lingli Kong, Qingfeng Shen, Caiyi Zhang, Guangli Liang, Xiaowei Zuo, Chengdong Wang, Bo Li, Xiuyuan Sun, Heng Wang, Xianghua Zhu
2017 Int J Clin Exp Med   unpublished
Objectives: To evaluate the cognitive improvement and assess the practice effects on patients with first-episode schizophrenia (FES) after accepting second-generation antipsychotic medications (SGAs): olanzapine and risperidone. Methods: A total of 98 patients with a diagnosis of schizophrenia and 63 healthy controls were randomly recruited in this study from Xuzhou East Hospital affiliated to Xuzhou Medical University and Qingdao mental health center and divided into 3 groups (olanzapine,
more » ... s (olanzapine, risperidone and healthy controls). The cognitive assessment and the neurocognitive detection would be taken for all groups and compared when appeared at baseline, six weeks later, and sixteen weeks later. The neurocognitive detections were inclusive of measurements of working memory and attention, speed, motor function, episodic memory, and executive function. Results: There was no significant different drug effect on cognitive performance between olanzapine and risperidone groups (P>0.05). The cognitive performance of both groups was improved. However, all cognitive evaluations for FES patients were obviously below those of HCs group (P<0.05). Besides, drug effects were bigger than practice effects in the cognitive tests in our study (P<0.005). Conclusion: To some extent, some cognitive improvements for the FES group may due to practice effects. However, differential medication effects on cognition were tiny in terms of our results in this study.